Here’s how Australia could reap the benefits from a stricter regulatory cannabis framework

Unregistered Cannabis Products Fail to Meet TGA Requirements

Unregistered Cannabis Products Fail to Meet TGA Requirements 22nd September, 2020The TGA’s recent Laboratories Testing Report on routine surveillance of unregistered products supplied to the Australian market via the SAS scheme has revealed that almost one quarter of samples received for testing failed to meet TG093 requirements relating to declarations made to the TGA regarding...
Read More
Q3 2020

FreshLeaf Q3 Market Report Press Release

Australia’s Most Comprehensive Medicinal Cannabis Report: Q3 2020 Thursday 17 September 2020FreshLeaf Analytics is excited to release Australia’s most comprehensive medicinal cannabis Patient, Product and Pricing Analysis.Q3 was defined by the greatest drop in product price since early 2016 legalisation of medicinal cannabis products in Australia, as the market has grown 3x year on year...
Read More
Cannabis stocks

ASX pot stocks are getting high after TGA interim ruling

Stockhead Cannabis stocks were one of the rare groups in the green on a dismal day for the ASX on Wednesday following an interim ruling by the Therapeutic Goods Administration that could boost the industry. The TGA is proposing to allow Australians to obtain low-dose cannabinoid (CBD) oils and pills from pharmacists, rather than forcing them to...
Read More
Australian export laws amended to boost industry

FreshLeaf Analytics S3

FreshLeaf Analytics welcomes TGA interim decision on CBD down-scheduling September 9th 2020Therapeutic Goods Administration (TGA) sticks to their guns on initial proposal for over-the-Counter low-dose CBD but no smoking, vaping, topicals. Potential $200M market in Australia.FreshLeaf Analytics has welcomed the interim decision today by the Therapeutic Goods Administration (TGA) to make registered low-dose CBD products...
Read More